WARF Therapeutics 2020 call for fall proposals

CONTACT:
Jacqui Fuller, Strategic Communications and Marketing Manager
[email protected] | 608.960.9881

Fall WARF Therapeutics (WT) Program Proposal Deadline: October 15

MADISON, Wis. – WARF Therapeutics encourages researchers working on a novel biological target to submit project proposals by October 15. The program works with researchers to advance work closer to clinical testing, a “bench to bedside” approach. It invests in the development of drug-like molecules using industry-centric drug discovery resources and a WARF Therapeutics team of preclinical drug discovery experts.

Projects Eligible for WARF Therapeutics

UW-Madison and Morgridge Institute for Research principal investigators
Working on translational research with either a validated target or have developed a therapeutic disease hypothesis
A patent is not required to work with WARF Therapeutics

WARF Therapeutics meets with researchers all year, but the WT board reviews proposals twice a year. Projects submitted by October 15 will have a review meeting in November. There will be another review in the spring. The current portfolio includes eight projects spanning the oncology, neuroscience, ophthalmology and fibrosis therapeutic areas.

Researchers are encouraged to set up a meeting with Jon Young to discuss their program and to learn more about WARF Therapeutics. Researchers can obtain the new program submission application online and submit their new program to Jon Young.

Seminar Series
WARF Therapeutics also partners with departments on campus to sponsor the WARF Therapeutics Drug Discovery seminar series. All are welcome to attend these upcoming virtual events.

November 13, 2020 | 10 a.m. CST | Webinar
Ben Cravatt, The Scripps Research Institute
Activity-based proteomics – ligand and protein discovery on a global scale
Cravatt earned his B.S. in biological sciences and a B.A. in history from Stanford University and his Ph.D. from Scripps Research Institute. He is a professor in the department of chemistry at Scripps Research Institute in San Diego.

November 13, 2020 | Noon CST | Webinar

Craig Erickson, MD, Cincinnati Children’s Hospital

Dr. Erickson’s group carries out preclinical and clinical research to develop new targeted drug treatments in developmental disabilities (autism spectrum disorders, Fragile X syndrome and Angelman syndrome). He is a leading expert in conducting clinical trials in individuals with Fragile X.

Visit our seminar series webpage to register and learn more.

If your department is interested in hosting a future event, please contact Jon Young, Head of WARF Therapeutics, at [email protected] or 608.960.9885.

About WARF Therapeutics

Consistent with WARF’s mission to support UW-Madison research and make a global impact, WARF Therapeutics is a major initiative to move new pharmaceuticals closer to the market and patients. The program will take select assets and lead them through preclinical development, towards commercialization and the benefit of human lives. More at warf.org/therapeutics.

About WARF
The Wisconsin Alumni Research Foundation (WARF) helps steward the cycle of research, discovery, commercialization and investment for the University of Wisconsin-Madison. Founded in 1925 as an independent, nonprofit foundation, WARF manages more than 2,000 patents and an investment portfolio as it funds university research, obtains patents for campus discoveries and licenses inventions to industry. For more information, visit warf.org.